[The use of lucetam for improvement of cognitive functions in chronic cerebrovascular insufficiency (clinical and encephalographic study)].
One hundred and ninety-three patients, aged 35-60 years, with chronic cerebrovascular insufficiency of I and II stage have been studied. It has been shown that memory and attention disturbances at stage I are of pseudomnemonic character. At stage II, the syndrome of mild cognitive impairment is formed first with the following formation of the moderate one. After the treatment with lucetam, the overall improvement as measured by neurophysiological testing was observed in 64% of patients, the memory improvement - in 18%, the attention improvement - in 10% and no positive effect was found in 8%. The significant improvement of cognitive functioning was correlated with positive changes of brain neurodynamics in the EEG study.
Bugrova
S G
SG
Novikov
A E
AE
D000328:Adult; D002561:Cerebrovascular Disorders / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D002908:Chronic Disease; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010889:Piracetam / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D018696:Neuroprotective Agents; D010889:Piracetam